vertex pharmaceuticals  wikipedia vertex pharmaceuticals from wikipedia the free encyclopedia jump to navigation search vertex pharmaceuticals incorporated type corporation traded as nasdaq vrtx nasdaq component sp  component industry pharmaceuticals  biotherapeutics founded  headquarters boston massachusetts key people jeffrey leiden md phd chair president and ceo stuart a arbuckle executive vice president and chief commercial officer kenneth l horton executive vice president and chief legal officer lisa kellycroswell senior vice president human resources david altshuler md phd executive vice president global research and chief scientific officer megan pace senior vice president corporate communications amit k sachdev senior vice president corporate affairs and public policy ian f smith executive vice president and chief financial officer products product pipeline revenue us billion  website wwwvrtxcom vertex pharmaceuticals is an american pharmaceutical company based in boston massachusetts vertex was founded in  by joshua boger and kevin j kinsella vertex was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry by  its product pipeline focused on viral infections inflammatory and autoimmune disorders and cancer it maintains headquarters in south boston massachusetts and two research facilities in san diego california and oxford england the companys beginnings were profiled by barry werth in the  book the billiondollar molecule and its further development in his  book the antidote inside the world of new pharma in  the company had about  employees including  in the boston area in january  vertex completed its move from cambridge massachusetts to boston massachusetts and took residence in a new  million complex located on the south boston waterfront it will mark the first time in the companys history that all of the roughly  vertex employees in the greater boston area will be working together since late  when jeffrey m leiden joined vertex as ceo vertex has ranked among the top  best performing companies on the standard  poor’s  vertex shares increased  percent in the same period vertex posted only one annual profit since it was founded in  contents  telaprevir  cystic fibrosis  ivacaftor  mrna therapeutics  venture philanthropy  see also  references  external links telapreviredit in may  the food and drug administration fda approved the drug telaprevir incivek an oral treatment for hepatitis c marketed by vertex development and commercialization of telaprevir is shared with johnson  johnson for european distribution and mitsubishi for asia telaprevir is a protease inhibitor cystic fibrosisedit ivacaftoredit in  ivacaftor was designated as an orphan drug identifying cystic fibrosis as affecting fewer than  people in the united states on january   vertex gained fda approval  of the first drug kalydeco to treat the underlying cause of cystic fibrosis rather than the symptoms in patients  years or older who have the gd gene mutation in the us  people have cystic fibrosis about  of those or  have the gd gene mutation vertex is marketing the drug at  a year per patient vertex also is studying ivacaftor in combination with another drug lumacaftor for the most common mutation in cf known as fdel and expects the first set of results in  vertex worked for  years with the cystic fibrosis foundation to develop the drug in the uk the company provided the drug free for a limited time for certain patients then left the hospitals to decide whether to continue to pay for it for those patients uk agencies estimated the cost per quality adjusted life year qaly at between £ and £—far above the nice thresholds of ££ on november   vertex announced the submission of a new drug application nda to the fda for a fully coformulated combination of lumacaftor and ivacaftor for people with cystic fibrosis ages  and older who have two copies of the fdel mutation in the cystic fibrosis transmembrane conductance regulator cftr gene in  fda approved orkambi lumacaftorivacaftor to treat cystic fibrosis cf in patients  years and older who have the fdel mutation mrna therapeuticsedit in  the company entered into a collaboration with moderna in fact taking an ownership stake in the company to develop new mrnabased therapeutics to treat cf venture philanthropyedit in the late s the bethesdabased cystic fibrosis foundation encouraged by thenpresident robert beall began investing in vertex— when it was a small startup biotechnology company— to help fund the development of kalydeco in the form of venture philanthropy the total investment amounted to  million in  the cf foundation sold the rights to the royalties of the drugs for  billion twenty times the foundation’s  budget by  the annual cost of kalydeco had risen to more than  per patient according to an article published in the milwaukee journal sentinel vertex executives grossed more than  million by cashing in stocks and stock options and at one point the value of companys stock increased more  billion in a single day twentynine physicians and scientists working with people with cystic fibrosis cf wrote to jeff leiden ceo of vertex pharmaceuticals to plead for lower prices we are aware of the financial complexities of the huge expenses for r  d with respect to the small number of patients or the market system that enables these advances to become reality yet  notwithstanding all your patient support programs  it is at best unseemly for vertex to charge our patients’ insurance plans including strapped state medical assistance plans  annually for two pills a day a fold increase in a typical patients total drug costs this action could appear to be leveraging pain and suffering into huge financial gain for speculators some of whom were your top executives who reportedly made millions of dollars in a single day boston globe may  — david m orenstein md et al the company responded in an email that while publicly funded academic research provided important early understanding of the cause of cystic fibrosis it took vertex scientists  years of their own research funded mostly by the company before the drug won approval on april   in cambridge ma joan finnegan brooks of the cystic fibrosis foundation spoke about the role of vertex and venture philanthropy to a panel of biotech leaders hosted by life sciences foundation on the topic of patient advocacy in the biotech industry while brooks who has cystic fibrosis expressed gratitude for vertex development of kalydeco she observed that  of cystic fibrosis patients are not getting the medical care they need because of the prohibitive cost of the drug see alsoedit companies portal cystic fibrosis foundation telaprevir referencesedit  vertex pharmaceuticals incorporated hoovers retrieved  june    a b weisman robert  april  rearranging the corporate dna boston sunday globe p g retrieved  june    a b werth barry  the billiondollar molecule one companys quest for the perfect drug new york simon  schuster isbn  oclc   the billiondollar molecule at google books  werth barry  the antidote inside the world of new pharma new york simon  schuster isbn  oclc    a b robert weisman  april  vertex chief’s compensation totaled  million last year total included a retention bonus boston globe retrieved  july    approval of incivek telaprevir a direct acting antiviral drug daa to treat hepatitis c hcv press release food and drug administration  may  retrieved  june    fda approves kalydeco to treat rare form of cystic fibrosis press release food and drug administration  january  retrieved  june    kalydeco™ ivacaftor tablets vertex pharmaceuticals retrieved  june    kalydeco a price too high to pay   vx cystic fibrosis vertex pharmaceuticals  september  retrieved  june    edney anna  february  vertex wins approval for kalydeco to treat cystic fibrosis bloomberg businessweek retrieved  june    deborah cohen james raftery  february  orphan drugs paying twice questions over high cost of cystic fibrosis drug developed with charitable funding bmj  g doibmjg   httpinvestorsvrtxcomreleasedetailcfmreleaseid  commissioner office of the press announcements  fda approves new treatment for cystic fibrosis wwwfdagov retrieved    vertex moderna launch cystic fibrosis collaboration news discovery  development genetic engineering  biotechnology news paper    august    a b andrew pollack november   deal by cystic fibrosis foundation raises cash and some concern new york times retrieved july     joseph walker jonathan d rockoff november   cystic fibrosis foundation sells drug’s rights for  billion the biggest royalty purchase ever reflects group’s share of kalydeco sales wall street journal retrieved july     brady dennis  july  are risks worth the rewards when nonprofits act like venture capitalists washington post retrieved  july    a b john fauber may   cystic fibrosis charity and industry partner for profit medpage today milwaukee journal sentinel retrieved july     david m orenstein paul m quinton brian p osullivan carlos e milla mark pian et al  july  letter to jeff leiden ceo of vertex pharmaceuticals pdf retrieved  july    a b voices carry how history informs patient advocacy in the biotech industry life sciences foundation cambridge massachusetts april   retrieved july    annual report vertex pharmaceuticals  march  retrieved  june   vertex completes new drug application for telaprevir for hepatitis c press release vertex pharmaceuticals  november  retrieved  june   external linksedit business data for vertex pharmaceuticals google finance yahoo finance reuters sec filings v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitlevertexpharmaceuticalsoldid categories companies in the nasdaq indexcompanies listed on nasdaqbiotechnology companies of the united statescompanies based in bostoncompanies established in companies in the nasdaq biotechnology indexorphan drug companieslife sciences industryhidden categories use dmy dates from june  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages españolفارسیfrançaissuomiукраїнськаtiếng việt edit links this page was last edited on  april  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view vertex pharmaceuticals  wikipedia vertex pharmaceuticals from wikipedia the free encyclopedia jump to navigation search vertex pharmaceuticals incorporated type corporation traded as nasdaq vrtx nasdaq component sp  component industry pharmaceuticals  biotherapeutics founded  headquarters boston massachusetts key people jeffrey leiden md phd chair president and ceo stuart a arbuckle executive vice president and chief commercial officer kenneth l horton executive vice president and chief legal officer lisa kellycroswell senior vice president human resources david altshuler md phd executive vice president global research and chief scientific officer megan pace senior vice president corporate communications amit k sachdev senior vice president corporate affairs and public policy ian f smith executive vice president and chief financial officer products product pipeline revenue us billion  website wwwvrtxcom vertex pharmaceuticals is an american pharmaceutical company based in boston massachusetts vertex was founded in  by joshua boger and kevin j kinsella vertex was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry by  its product pipeline focused on viral infections inflammatory and autoimmune disorders and cancer it maintains headquarters in south boston massachusetts and two research facilities in san diego california and oxford england the companys beginnings were profiled by barry werth in the  book the billiondollar molecule and its further development in his  book the antidote inside the world of new pharma in  the company had about  employees including  in the boston area in january  vertex completed its move from cambridge massachusetts to boston massachusetts and took residence in a new  million complex located on the south boston waterfront it will mark the first time in the companys history that all of the roughly  vertex employees in the greater boston area will be working together since late  when jeffrey m leiden joined vertex as ceo vertex has ranked among the top  best performing companies on the standard  poor’s  vertex shares increased  percent in the same period vertex posted only one annual profit since it was founded in  contents  telaprevir  cystic fibrosis  ivacaftor  mrna therapeutics  venture philanthropy  see also  references  external links telapreviredit in may  the food and drug administration fda approved the drug telaprevir incivek an oral treatment for hepatitis c marketed by vertex development and commercialization of telaprevir is shared with johnson  johnson for european distribution and mitsubishi for asia telaprevir is a protease inhibitor cystic fibrosisedit ivacaftoredit in  ivacaftor was designated as an orphan drug identifying cystic fibrosis as affecting fewer than  people in the united states on january   vertex gained fda approval  of the first drug kalydeco to treat the underlying cause of cystic fibrosis rather than the symptoms in patients  years or older who have the gd gene mutation in the us  people have cystic fibrosis about  of those or  have the gd gene mutation vertex is marketing the drug at  a year per patient vertex also is studying ivacaftor in combination with another drug lumacaftor for the most common mutation in cf known as fdel and expects the first set of results in  vertex worked for  years with the cystic fibrosis foundation to develop the drug in the uk the company provided the drug free for a limited time for certain patients then left the hospitals to decide whether to continue to pay for it for those patients uk agencies estimated the cost per quality adjusted life year qaly at between £ and £—far above the nice thresholds of ££ on november   vertex announced the submission of a new drug application nda to the fda for a fully coformulated combination of lumacaftor and ivacaftor for people with cystic fibrosis ages  and older who have two copies of the fdel mutation in the cystic fibrosis transmembrane conductance regulator cftr gene in  fda approved orkambi lumacaftorivacaftor to treat cystic fibrosis cf in patients  years and older who have the fdel mutation mrna therapeuticsedit in  the company entered into a collaboration with moderna in fact taking an ownership stake in the company to develop new mrnabased therapeutics to treat cf venture philanthropyedit in the late s the bethesdabased cystic fibrosis foundation encouraged by thenpresident robert beall began investing in vertex— when it was a small startup biotechnology company— to help fund the development of kalydeco in the form of venture philanthropy the total investment amounted to  million in  the cf foundation sold the rights to the royalties of the drugs for  billion twenty times the foundation’s  budget by  the annual cost of kalydeco had risen to more than  per patient according to an article published in the milwaukee journal sentinel vertex executives grossed more than  million by cashing in stocks and stock options and at one point the value of companys stock increased more  billion in a single day twentynine physicians and scientists working with people with cystic fibrosis cf wrote to jeff leiden ceo of vertex pharmaceuticals to plead for lower prices we are aware of the financial complexities of the huge expenses for r  d with respect to the small number of patients or the market system that enables these advances to become reality yet  notwithstanding all your patient support programs  it is at best unseemly for vertex to charge our patients’ insurance plans including strapped state medical assistance plans  annually for two pills a day a fold increase in a typical patients total drug costs this action could appear to be leveraging pain and suffering into huge financial gain for speculators some of whom were your top executives who reportedly made millions of dollars in a single day boston globe may  — david m orenstein md et al the company responded in an email that while publicly funded academic research provided important early understanding of the cause of cystic fibrosis it took vertex scientists  years of their own research funded mostly by the company before the drug won approval on april   in cambridge ma joan finnegan brooks of the cystic fibrosis foundation spoke about the role of vertex and venture philanthropy to a panel of biotech leaders hosted by life sciences foundation on the topic of patient advocacy in the biotech industry while brooks who has cystic fibrosis expressed gratitude for vertex development of kalydeco she observed that  of cystic fibrosis patients are not getting the medical care they need because of the prohibitive cost of the drug see alsoedit companies portal cystic fibrosis foundation telaprevir referencesedit  vertex pharmaceuticals incorporated hoovers retrieved  june    a b weisman robert  april  rearranging the corporate dna boston sunday globe p g retrieved  june    a b werth barry  the billiondollar molecule one companys quest for the perfect drug new york simon  schuster isbn  oclc   the billiondollar molecule at google books  werth barry  the antidote inside the world of new pharma new york simon  schuster isbn  oclc    a b robert weisman  april  vertex chief’s compensation totaled  million last year total included a retention bonus boston globe retrieved  july    approval of incivek telaprevir a direct acting antiviral drug daa to treat hepatitis c hcv press release food and drug administration  may  retrieved  june    fda approves kalydeco to treat rare form of cystic fibrosis press release food and drug administration  january  retrieved  june    kalydeco™ ivacaftor tablets vertex pharmaceuticals retrieved  june    kalydeco a price too high to pay   vx cystic fibrosis vertex pharmaceuticals  september  retrieved  june    edney anna  february  vertex wins approval for kalydeco to treat cystic fibrosis bloomberg businessweek retrieved  june    deborah cohen james raftery  february  orphan drugs paying twice questions over high cost of cystic fibrosis drug developed with charitable funding bmj  g doibmjg   httpinvestorsvrtxcomreleasedetailcfmreleaseid  commissioner office of the press announcements  fda approves new treatment for cystic fibrosis wwwfdagov retrieved    vertex moderna launch cystic fibrosis collaboration news discovery  development genetic engineering  biotechnology news paper    august    a b andrew pollack november   deal by cystic fibrosis foundation raises cash and some concern new york times retrieved july     joseph walker jonathan d rockoff november   cystic fibrosis foundation sells drug’s rights for  billion the biggest royalty purchase ever reflects group’s share of kalydeco sales wall street journal retrieved july     brady dennis  july  are risks worth the rewards when nonprofits act like venture capitalists washington post retrieved  july    a b john fauber may   cystic fibrosis charity and industry partner for profit medpage today milwaukee journal sentinel retrieved july     david m orenstein paul m quinton brian p osullivan carlos e milla mark pian et al  july  letter to jeff leiden ceo of vertex pharmaceuticals pdf retrieved  july    a b voices carry how history informs patient advocacy in the biotech industry life sciences foundation cambridge massachusetts april   retrieved july    annual report vertex pharmaceuticals  march  retrieved  june   vertex completes new drug application for telaprevir for hepatitis c press release vertex pharmaceuticals  november  retrieved  june   external linksedit business data for vertex pharmaceuticals google finance yahoo finance reuters sec filings v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitlevertexpharmaceuticalsoldid categories companies in the nasdaq indexcompanies listed on nasdaqbiotechnology companies of the united statescompanies based in bostoncompanies established in companies in the nasdaq biotechnology indexorphan drug companieslife sciences industryhidden categories use dmy dates from june  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages españolفارسیfrançaissuomiукраїнськаtiếng việt edit links this page was last edited on  april  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view vertex pharmaceuticals  wikipedia vertex pharmaceuticals from wikipedia the free encyclopedia jump to navigation search vertex pharmaceuticals incorporated type corporation traded as nasdaq vrtx nasdaq component sp  component industry pharmaceuticals  biotherapeutics founded  headquarters boston massachusetts key people jeffrey leiden md phd chair president and ceo stuart a arbuckle executive vice president and chief commercial officer kenneth l horton executive vice president and chief legal officer lisa kellycroswell senior vice president human resources david altshuler md phd executive vice president global research and chief scientific officer megan pace senior vice president corporate communications amit k sachdev senior vice president corporate affairs and public policy ian f smith executive vice president and chief financial officer products product pipeline revenue us billion  website wwwvrtxcom vertex pharmaceuticals is an american pharmaceutical company based in boston massachusetts vertex was founded in  by joshua boger and kevin j kinsella vertex was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry by  its product pipeline focused on viral infections inflammatory and autoimmune disorders and cancer it maintains headquarters in south boston massachusetts and two research facilities in san diego california and oxford england the companys beginnings were profiled by barry werth in the  book the billiondollar molecule and its further development in his  book the antidote inside the world of new pharma in  the company had about  employees including  in the boston area in january  vertex completed its move from cambridge massachusetts to boston massachusetts and took residence in a new  million complex located on the south boston waterfront it will mark the first time in the companys history that all of the roughly  vertex employees in the greater boston area will be working together since late  when jeffrey m leiden joined vertex as ceo vertex has ranked among the top  best performing companies on the standard  poor’s  vertex shares increased  percent in the same period vertex posted only one annual profit since it was founded in  contents  telaprevir  cystic fibrosis  ivacaftor  mrna therapeutics  venture philanthropy  see also  references  external links telapreviredit in may  the food and drug administration fda approved the drug telaprevir incivek an oral treatment for hepatitis c marketed by vertex development and commercialization of telaprevir is shared with johnson  johnson for european distribution and mitsubishi for asia telaprevir is a protease inhibitor cystic fibrosisedit ivacaftoredit in  ivacaftor was designated as an orphan drug identifying cystic fibrosis as affecting fewer than  people in the united states on january   vertex gained fda approval  of the first drug kalydeco to treat the underlying cause of cystic fibrosis rather than the symptoms in patients  years or older who have the gd gene mutation in the us  people have cystic fibrosis about  of those or  have the gd gene mutation vertex is marketing the drug at  a year per patient vertex also is studying ivacaftor in combination with another drug lumacaftor for the most common mutation in cf known as fdel and expects the first set of results in  vertex worked for  years with the cystic fibrosis foundation to develop the drug in the uk the company provided the drug free for a limited time for certain patients then left the hospitals to decide whether to continue to pay for it for those patients uk agencies estimated the cost per quality adjusted life year qaly at between £ and £—far above the nice thresholds of ££ on november   vertex announced the submission of a new drug application nda to the fda for a fully coformulated combination of lumacaftor and ivacaftor for people with cystic fibrosis ages  and older who have two copies of the fdel mutation in the cystic fibrosis transmembrane conductance regulator cftr gene in  fda approved orkambi lumacaftorivacaftor to treat cystic fibrosis cf in patients  years and older who have the fdel mutation mrna therapeuticsedit in  the company entered into a collaboration with moderna in fact taking an ownership stake in the company to develop new mrnabased therapeutics to treat cf venture philanthropyedit in the late s the bethesdabased cystic fibrosis foundation encouraged by thenpresident robert beall began investing in vertex— when it was a small startup biotechnology company— to help fund the development of kalydeco in the form of venture philanthropy the total investment amounted to  million in  the cf foundation sold the rights to the royalties of the drugs for  billion twenty times the foundation’s  budget by  the annual cost of kalydeco had risen to more than  per patient according to an article published in the milwaukee journal sentinel vertex executives grossed more than  million by cashing in stocks and stock options and at one point the value of companys stock increased more  billion in a single day twentynine physicians and scientists working with people with cystic fibrosis cf wrote to jeff leiden ceo of vertex pharmaceuticals to plead for lower prices we are aware of the financial complexities of the huge expenses for r  d with respect to the small number of patients or the market system that enables these advances to become reality yet  notwithstanding all your patient support programs  it is at best unseemly for vertex to charge our patients’ insurance plans including strapped state medical assistance plans  annually for two pills a day a fold increase in a typical patients total drug costs this action could appear to be leveraging pain and suffering into huge financial gain for speculators some of whom were your top executives who reportedly made millions of dollars in a single day boston globe may  — david m orenstein md et al the company responded in an email that while publicly funded academic research provided important early understanding of the cause of cystic fibrosis it took vertex scientists  years of their own research funded mostly by the company before the drug won approval on april   in cambridge ma joan finnegan brooks of the cystic fibrosis foundation spoke about the role of vertex and venture philanthropy to a panel of biotech leaders hosted by life sciences foundation on the topic of patient advocacy in the biotech industry while brooks who has cystic fibrosis expressed gratitude for vertex development of kalydeco she observed that  of cystic fibrosis patients are not getting the medical care they need because of the prohibitive cost of the drug see alsoedit companies portal cystic fibrosis foundation telaprevir referencesedit  vertex pharmaceuticals incorporated hoovers retrieved  june    a b weisman robert  april  rearranging the corporate dna boston sunday globe p g retrieved  june    a b werth barry  the billiondollar molecule one companys quest for the perfect drug new york simon  schuster isbn  oclc   the billiondollar molecule at google books  werth barry  the antidote inside the world of new pharma new york simon  schuster isbn  oclc    a b robert weisman  april  vertex chief’s compensation totaled  million last year total included a retention bonus boston globe retrieved  july    approval of incivek telaprevir a direct acting antiviral drug daa to treat hepatitis c hcv press release food and drug administration  may  retrieved  june    fda approves kalydeco to treat rare form of cystic fibrosis press release food and drug administration  january  retrieved  june    kalydeco™ ivacaftor tablets vertex pharmaceuticals retrieved  june    kalydeco a price too high to pay   vx cystic fibrosis vertex pharmaceuticals  september  retrieved  june    edney anna  february  vertex wins approval for kalydeco to treat cystic fibrosis bloomberg businessweek retrieved  june    deborah cohen james raftery  february  orphan drugs paying twice questions over high cost of cystic fibrosis drug developed with charitable funding bmj  g doibmjg   httpinvestorsvrtxcomreleasedetailcfmreleaseid  commissioner office of the press announcements  fda approves new treatment for cystic fibrosis wwwfdagov retrieved    vertex moderna launch cystic fibrosis collaboration news discovery  development genetic engineering  biotechnology news paper    august    a b andrew pollack november   deal by cystic fibrosis foundation raises cash and some concern new york times retrieved july     joseph walker jonathan d rockoff november   cystic fibrosis foundation sells drug’s rights for  billion the biggest royalty purchase ever reflects group’s share of kalydeco sales wall street journal retrieved july     brady dennis  july  are risks worth the rewards when nonprofits act like venture capitalists washington post retrieved  july    a b john fauber may   cystic fibrosis charity and industry partner for profit medpage today milwaukee journal sentinel retrieved july     david m orenstein paul m quinton brian p osullivan carlos e milla mark pian et al  july  letter to jeff leiden ceo of vertex pharmaceuticals pdf retrieved  july    a b voices carry how history informs patient advocacy in the biotech industry life sciences foundation cambridge massachusetts april   retrieved july    annual report vertex pharmaceuticals  march  retrieved  june   vertex completes new drug application for telaprevir for hepatitis c press release vertex pharmaceuticals  november  retrieved  june   external linksedit business data for vertex pharmaceuticals google finance yahoo finance reuters sec filings v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitlevertexpharmaceuticalsoldid categories companies in the nasdaq indexcompanies listed on nasdaqbiotechnology companies of the united statescompanies based in bostoncompanies established in companies in the nasdaq biotechnology indexorphan drug companieslife sciences industryhidden categories use dmy dates from june  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages españolفارسیfrançaissuomiукраїнськаtiếng việt edit links this page was last edited on  april  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view vertex pharmaceuticals  wikipedia vertex pharmaceuticals from wikipedia the free encyclopedia jump to navigation search vertex pharmaceuticals incorporated type corporation traded as nasdaq vrtx nasdaq component sp  component industry pharmaceuticals  biotherapeutics founded  headquarters boston massachusetts key people jeffrey leiden md phd chair president and ceo stuart a arbuckle executive vice president and chief commercial officer kenneth l horton executive vice president and chief legal officer lisa kellycroswell senior vice president human resources david altshuler md phd executive vice president global research and chief scientific officer megan pace senior vice president corporate communications amit k sachdev senior vice president corporate affairs and public policy ian f smith executive vice president and chief financial officer products product pipeline revenue us billion  website wwwvrtxcom vertex pharmaceuticals is an american pharmaceutical company based in boston massachusetts vertex was founded in  by joshua boger and kevin j kinsella vertex was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry by  its product pipeline focused on viral infections inflammatory and autoimmune disorders and cancer it maintains headquarters in south boston massachusetts and two research facilities in san diego california and oxford england the companys beginnings were profiled by barry werth in the  book the billiondollar molecule and its further development in his  book the antidote inside the world of new pharma in  the company had about  employees including  in the boston area in january  vertex completed its move from cambridge massachusetts to boston massachusetts and took residence in a new  million complex located on the south boston waterfront it will mark the first time in the companys history that all of the roughly  vertex employees in the greater boston area will be working together since late  when jeffrey m leiden joined vertex as ceo vertex has ranked among the top  best performing companies on the standard  poor’s  vertex shares increased  percent in the same period vertex posted only one annual profit since it was founded in  contents  telaprevir  cystic fibrosis  ivacaftor  mrna therapeutics  venture philanthropy  see also  references  external links telapreviredit in may  the food and drug administration fda approved the drug telaprevir incivek an oral treatment for hepatitis c marketed by vertex development and commercialization of telaprevir is shared with johnson  johnson for european distribution and mitsubishi for asia telaprevir is a protease inhibitor cystic fibrosisedit ivacaftoredit in  ivacaftor was designated as an orphan drug identifying cystic fibrosis as affecting fewer than  people in the united states on january   vertex gained fda approval  of the first drug kalydeco to treat the underlying cause of cystic fibrosis rather than the symptoms in patients  years or older who have the gd gene mutation in the us  people have cystic fibrosis about  of those or  have the gd gene mutation vertex is marketing the drug at  a year per patient vertex also is studying ivacaftor in combination with another drug lumacaftor for the most common mutation in cf known as fdel and expects the first set of results in  vertex worked for  years with the cystic fibrosis foundation to develop the drug in the uk the company provided the drug free for a limited time for certain patients then left the hospitals to decide whether to continue to pay for it for those patients uk agencies estimated the cost per quality adjusted life year qaly at between £ and £—far above the nice thresholds of ££ on november   vertex announced the submission of a new drug application nda to the fda for a fully coformulated combination of lumacaftor and ivacaftor for people with cystic fibrosis ages  and older who have two copies of the fdel mutation in the cystic fibrosis transmembrane conductance regulator cftr gene in  fda approved orkambi lumacaftorivacaftor to treat cystic fibrosis cf in patients  years and older who have the fdel mutation mrna therapeuticsedit in  the company entered into a collaboration with moderna in fact taking an ownership stake in the company to develop new mrnabased therapeutics to treat cf venture philanthropyedit in the late s the bethesdabased cystic fibrosis foundation encouraged by thenpresident robert beall began investing in vertex— when it was a small startup biotechnology company— to help fund the development of kalydeco in the form of venture philanthropy the total investment amounted to  million in  the cf foundation sold the rights to the royalties of the drugs for  billion twenty times the foundation’s  budget by  the annual cost of kalydeco had risen to more than  per patient according to an article published in the milwaukee journal sentinel vertex executives grossed more than  million by cashing in stocks and stock options and at one point the value of companys stock increased more  billion in a single day twentynine physicians and scientists working with people with cystic fibrosis cf wrote to jeff leiden ceo of vertex pharmaceuticals to plead for lower prices we are aware of the financial complexities of the huge expenses for r  d with respect to the small number of patients or the market system that enables these advances to become reality yet  notwithstanding all your patient support programs  it is at best unseemly for vertex to charge our patients’ insurance plans including strapped state medical assistance plans  annually for two pills a day a fold increase in a typical patients total drug costs this action could appear to be leveraging pain and suffering into huge financial gain for speculators some of whom were your top executives who reportedly made millions of dollars in a single day boston globe may  — david m orenstein md et al the company responded in an email that while publicly funded academic research provided important early understanding of the cause of cystic fibrosis it took vertex scientists  years of their own research funded mostly by the company before the drug won approval on april   in cambridge ma joan finnegan brooks of the cystic fibrosis foundation spoke about the role of vertex and venture philanthropy to a panel of biotech leaders hosted by life sciences foundation on the topic of patient advocacy in the biotech industry while brooks who has cystic fibrosis expressed gratitude for vertex development of kalydeco she observed that  of cystic fibrosis patients are not getting the medical care they need because of the prohibitive cost of the drug see alsoedit companies portal cystic fibrosis foundation telaprevir referencesedit  vertex pharmaceuticals incorporated hoovers retrieved  june    a b weisman robert  april  rearranging the corporate dna boston sunday globe p g retrieved  june    a b werth barry  the billiondollar molecule one companys quest for the perfect drug new york simon  schuster isbn  oclc   the billiondollar molecule at google books  werth barry  the antidote inside the world of new pharma new york simon  schuster isbn  oclc    a b robert weisman  april  vertex chief’s compensation totaled  million last year total included a retention bonus boston globe retrieved  july    approval of incivek telaprevir a direct acting antiviral drug daa to treat hepatitis c hcv press release food and drug administration  may  retrieved  june    fda approves kalydeco to treat rare form of cystic fibrosis press release food and drug administration  january  retrieved  june    kalydeco™ ivacaftor tablets vertex pharmaceuticals retrieved  june    kalydeco a price too high to pay   vx cystic fibrosis vertex pharmaceuticals  september  retrieved  june    edney anna  february  vertex wins approval for kalydeco to treat cystic fibrosis bloomberg businessweek retrieved  june    deborah cohen james raftery  february  orphan drugs paying twice questions over high cost of cystic fibrosis drug developed with charitable funding bmj  g doibmjg   httpinvestorsvrtxcomreleasedetailcfmreleaseid  commissioner office of the press announcements  fda approves new treatment for cystic fibrosis wwwfdagov retrieved    vertex moderna launch cystic fibrosis collaboration news discovery  development genetic engineering  biotechnology news paper    august    a b andrew pollack november   deal by cystic fibrosis foundation raises cash and some concern new york times retrieved july     joseph walker jonathan d rockoff november   cystic fibrosis foundation sells drug’s rights for  billion the biggest royalty purchase ever reflects group’s share of kalydeco sales wall street journal retrieved july     brady dennis  july  are risks worth the rewards when nonprofits act like venture capitalists washington post retrieved  july    a b john fauber may   cystic fibrosis charity and industry partner for profit medpage today milwaukee journal sentinel retrieved july     david m orenstein paul m quinton brian p osullivan carlos e milla mark pian et al  july  letter to jeff leiden ceo of vertex pharmaceuticals pdf retrieved  july    a b voices carry how history informs patient advocacy in the biotech industry life sciences foundation cambridge massachusetts april   retrieved july    annual report vertex pharmaceuticals  march  retrieved  june   vertex completes new drug application for telaprevir for hepatitis c press release vertex pharmaceuticals  november  retrieved  june   external linksedit business data for vertex pharmaceuticals google finance yahoo finance reuters sec filings v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitlevertexpharmaceuticalsoldid categories companies in the nasdaq indexcompanies listed on nasdaqbiotechnology companies of the united statescompanies based in bostoncompanies established in companies in the nasdaq biotechnology indexorphan drug companieslife sciences industryhidden categories use dmy dates from june  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version in other projects wikimedia commons languages españolفارسیfrançaissuomiукраїнськаtiếng việt edit links this page was last edited on  april  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view joshua boger  the alliance for business leadership inc  zoominfocom joshua boger  founder at new england healthcare institute news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink joshua boger founder at new england healthcare institute overview in the news relationships paths education career history boards  committees nonprofit donations  grants political donations investments public holdings awards  honors joshua boger founder at new england healthcare institute overview age  born  notable companies alkeus pharmaceuticals inc new england healthcare institute vertex pharmaceuticals inc awards  board seats  number of relationships this person is connected to  people in the news see more the boston globe june   a mass exodus of rich folks not likelystudies suggest proposal for additional income tax wont prompt top earners to flee the boston globe march   senate race weighs on baker team boston herald february   biz alliance to gov fight prez’s immigration policy the boston globe july   experimental drug shows promise in treating postpartum depression the boston globe july   highrise units lowprofile namesnew luxury tower reveals first deeds of condominiums see full news coverage and complete stories with relsci professional create your news feed see more relationships see details jonathan j fleming managing general partner at oxford bioscience partners jeffrey m leiden chief executive officer  president at vertex pharmaceuticals inc john fallon chief physician executive at new england healthcare institute josef h von rickenbach founder at parexel international corp eve s slater professor at columbia university  college of physicians and surgeons christopher m coburn chief innovation officer at partners healthcare system inc james roosevelt jr secretary  director at massachusetts association of health plans inc david p meeker former director pulmonary critical care fellowship at cleveland clinic michael roth president at wesleyan university murray n ross former chair board of directors at new england healthcare institute see  more listings with relsci professional start my free trial ➤ see  more paths to joshua boger joshua boger you connections via relationship science joshua boger sync your contacts to see how you can connect with joshua boger start my free trial ➤ see more educational background ba chemistry  philosoph  class of   wesleyan university wesleyan university is known for the excellence of its academic and cocurricular programs about  undergraduates—and some  graduate students—from around the world pursue their classroom studies research projects and cocurricular interests in ways that are demanding and intensely rewarding here on a beautiful campus overlooking the connecticut river students learn to do productive and innovative work that makes a positive difference in the world—that’s what wesleyan is about ms in chemistry  harvard university harvard was established in  and it is the oldest institution of higher education in the united states the university which is based in cambridge and boston massachusetts has an enrollment of over  degree candidates including undergraduate graduate and professional students the university has twelve degreegranting schools in addition to the radcliffe institute for advanced study career history executive chairman   current alkeus pharmaceuticals inc alkeus pharmaceuticals inc operates as a clinical stage drug discovery and development company the company was founded by leonide saad joshua boger and ilyas washington in  and is headquartered in boston ma founder current new england healthcare institute nehi is an independent nonprofit organization dedicated to transforming health care for the benefit of patients and their families through collaboration with members from all across the health care system nehi conducts evidencebased research and simulates policy change to improve the quality safety and affordability of health care together with this unparalleled network of committed health care leaders nehi brings an objective collaborative and fresh voice to health policy founder    vertex pharmaceuticals inc vertex pharmaceuticals inc engages in the business of discovering developing manufacturing and commercializing small molecule drugs for patients with serious diseases it focuses on development and commercializing therapies for the treatment of cystic fibrosis infectious diseases including viral infections such as influenza and bacterial infections autoimmune diseases such as rheumatoid arthritis cancer inflammatory bowel disease and neurological disorders including pain huntingtons disease and multiple sclerosis the company was founded by joshua s boger in  and is headquartered in boston ma senior director of basic chemistry   prior merck sharp  dohme research laboratories senior director basic chemistry prior merck  co inc merck  co inc  dba merck sharp  dohme msd outside the united states and canada is an american pharmaceutical company and is one of the largest pharmaceutical companies in the world boards  committees corporate boards ▾ vice chair board of trustees current museum of science museum of science operates as a museum the company was founded in  and is headquartered in boston ma chairman board of directors    vertex pharmaceuticals inc vertex pharmaceuticals inc engages in the business of discovering developing manufacturing and commercializing small molecule drugs for patients with serious diseases it focuses on development and commercializing therapies for the treatment of cystic fibrosis infectious diseases including viral infections such as influenza and bacterial infections autoimmune diseases such as rheumatoid arthritis cancer inflammatory bowel disease and neurological disorders including pain huntingtons disease and multiple sclerosis the company was founded by joshua s boger in  and is headquartered in boston ma director prior activbiotics inc activbiotics inc discovers and develops pharmaceutical drugs it provides discovery development and commercialization of therapies for the treatment of vascular disease inflammation and other highvalue chronic and infectious diseases the company was founded in  and is headquartered in lexington ma director prior massachusetts life sciences center the massachusetts life sciences center mlsc is a quasipublic agency of the commonwealth of massachusetts tasked with implementing the massachusetts life sciences act a tenyear  billion initiative that was signed into law in june of  the centers mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition this work includes making financial investments in public and private institutions that are advancing life sciences research development and commercialization as well as building ties between sectors of the massachusetts life sciences community nonprofit boards ▾ chair board of directors current celebrity series of boston inc to present worldclass performing artists who inspire and enrich our community we believe in the power of excellence and innovation in the performing arts to enrich life experience transform lives and build better communities we envision a community of greater boston where the performing arts are a valued lifelong shared experience  on stages inschools in homes  everywhere member board of fellows current harvard university  harvard medical school harvard medical school hms is the graduate medical school of harvard university it is located in the longwood medical area of the mission hill neighborhood of boston massachusettsthe school was founded by john warren on september   with benjamin waterhouse and aaron dexter vice chair board of directors current the alliance for business leadership member science visiting council current wgbh wgbh is a local public broadcaster serving southern new england with  public television services three public radio services and local productions from greater boston to classical music with laura carlo that reflect the issues and cultural riches of the region honorary member board of advisors current the greater boston food bank inc the greater boston food bank distributes more than  million pounds of food and grocery products annually to approximately  member hungerrelief agencies and  food bank direct service programs throughout eastern massachusetts in a dedicated partnership to end hunger in our region the food bank is a member of feeding america the nation’s food bank network member board of governors prior   longy school of music longy school of music is an american private company located in cambridge ma with domestic subsidiaries that provides educational services chair board of trustees prior   wesleyan university wesleyan university is known for the excellence of its academic and cocurricular programs about  undergraduates—and some  graduate students—from around the world pursue their classroom studies research projects and cocurricular interests in ways that are demanding and intensely rewarding here on a beautiful campus overlooking the connecticut river students learn to do productive and innovative work that makes a positive difference in the world—that’s what wesleyan is about director prior   whitehead institute for biomedical research whitehead institute for biomedical research provides research and technology services its services include biomedical genomics and genetics for students the company was founded by edwin c whitehead in  and is headquartered in cambridge ma director    biotechnology innovation organization biotechnology innovation organization is the worlds biotechnology organization providing advocacy business development and communications services for more than  members worldwide bio members are involved in the research and development of innovative healthcare agricultural industrial and environmental biotechnology technologies corporate members range from entrepreneurial companies developing a first product to fortune  multinationals also represent state and regional biotech associations service providers to the industry and academic centers member board of directors prior new england healthcare institute nehi is an independent nonprofit organization dedicated to transforming health care for the benefit of patients and their families through collaboration with members from all across the health care system nehi conducts evidencebased research and simulates policy change to improve the quality safety and affordability of health care together with this unparalleled network of committed health care leaders nehi brings an objective collaborative and fresh voice to health policy chairman prior massachusetts high technology council inc massachusetts high technology council is to help make massachusetts the worlds most attractive place in which to live and work and in which to create operate and grow high technology businesses director prior american civil liberties union foundation inc american civil liberties union foundation inc funds litigation and public education work the company was founded by roger baldwin crystal eastman and albert desilver in  and is headquartered in new york ny board member prior the hastings center with a small staff of senior researchers at the center and drawing upon an internationally renowned group of more than  elected fellows the hastings center pursues interdisciplinary research and education that includes both theory and practice founded in  by philosopher daniel callahan and psychoanalyst willard gaylin the hastings center is the oldest independent nonpartisan interdisciplinary research institute of its kind in the world from its earliest days the center has understood that the moral problems arising from rapid advances in medicine and biology are set within a broad intellectual and social context the centers collaborations with policymakers in the private as well as the public sphere assist them in analyzing the ethical dimensions of their work member visiting committee prior harvard t h chan school of public health the harvard school of public health hsph is one of the professional graduate schools of harvard university located in the longwood area of boston massachusetts neighborhood of mission hill which is next to harvard medical school hsph is considered a significant school focusing on health in the united states harvard school of public health grew out of the harvardmit school for health officers the nations first graduate training program in population health which was founded in  and became harvard school of public health in  julio frenk the minister of health of mexico from  to  and a former executive director of the world health organization who became the new dean of hsph in january  member board of directors prior massachusetts workforce board association trustee tenure unconfirmed american civil liberties union foundation of massachusetts aclu foundation of ma was established to defend freedoms guaranteed in the constitution and bill of rights through public education and litigation nonprofit donations  grants m  wesleyan university wesleyan university is known for the excellence of its academic and cocurricular programs about  undergraduates—and some  graduate students—from around the world pursue their classroom studies research projects and cocurricular interests in ways that are demanding and intensely rewarding here on a beautiful campus overlooking the connecticut river students learn to do productive and innovative work that makes a positive difference in the world—that’s what wesleyan is about k  k  the greater boston food bank inc the greater boston food bank distributes more than  million pounds of food and grocery products annually to approximately  member hungerrelief agencies and  food bank direct service programs throughout eastern massachusetts in a dedicated partnership to end hunger in our region the food bank is a member of feeding america the nation’s food bank network     sudbury valley trustees     the carter center inc the carter center inc provides human rights protection services the firms services include resolving conflicts advancing democracy human rights and economic opportunity preventing diseases improving mental health care and teaching farmers to increase crop production the company was founded in  by former us president jimmy carter and his wife rosalynn in partnership with emory university and is headquartered in atlanta ga k  k  the greater boston food bank inc the greater boston food bank distributes more than  million pounds of food and grocery products annually to approximately  member hungerrelief agencies and  food bank direct service programs throughout eastern massachusetts in a dedicated partnership to end hunger in our region the food bank is a member of feeding america the nation’s food bank network see  more listings with relsci professional start my free trial ➤ see  more political donations   michael f bennet senator from colorado   edward j markey representative from massachusettss th congressional district   michael f bennet senator from colorado   edward j markey representative from massachusettss th congressional district k  ohio democratic party see  more listings with relsci professional start my free trial ➤ see  more investments details hidden mom incubators ltd mom incubators ltd designs and develops infant incubator for premature babies the company was founded by james michael roberts and matthew khoory on november   and is headquartered in london the united kingdom public holdings restricted data only for relsci professional users start my free trial ➤ see more awards  honors  world economic forum  technology pioneers sponsored by the world economic forum other affiliations joshua boger is affiliated with alkeus pharmaceuticals inc new england healthcare institute vertex pharmaceuticals inc merck sharp  dohme research laboratories merck  co inc museum of science vertex pharmaceuticals inc activbiotics inc massachusetts life sciences center celebrity series of boston inc harvard university  harvard medical school the alliance for business leadership wgbh the greater boston food bank inc longy school of music wesleyan university whitehead institute for biomedical research biotechnology innovation organization new england healthcare institute massachusetts high technology council inc american civil liberties union foundation inc the hastings center harvard t h chan school of public health massachusetts workforce board association american civil liberties union foundation of massachusetts youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ joshua s boger phd  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in joshua s boger phd board member at vertex pharmaceuticals incorporated view full profile are you joshua s boger phd claim your profile   sign up for equilar atlas and view joshua s boger phds full profile with equilar atlas you can identify corporate executives in joshua s boger phds network and community follow changes in joshua s boger phds employment and moneyinmotion connect with joshua s boger phd through your network of contacts joshua s boger phds executive work history current board member vertex pharmaceuticals incorporated past to view joshua s boger phds complete executive work history sign up now education ba wesleyan university ms harvard university age      joshua s boger phds biography dr boger is the founder of vertex and has been a director since our inception in  he was our chief executive officer from  through may  he was our chairman of our board of directors from  until may  and our president from our inception until december  and from  through february  he was our chief scientific officer from  until may  prior to founding vertex in  dr boger held the position of senior director of basic chemistry at merck sharp  dohme research laboratories in rahway new jersey where he headed both the department of medicinal chemistry of immunology  inflammation and the departm  read more dr boger is the founder of vertex and has been a director since our inception in  he was our chief executive officer from  through may  he was our chairman of our board of directors from  until may  and our president from our inception until december  and from  through february  he was our chief scientific officer from  until may  prior to founding vertex in  dr boger held the position of senior director of basic chemistry at merck sharp  dohme research laboratories in rahway new jersey where he headed both the department of medicinal chemistry of immunology  inflammation and the department of biophysical chemistry dr boger holds a ba in chemistry and philosophy from wesleyan university and ms and phd degrees in chemistry from harvard university skills and qualifications dr bogers qualifications for our board of directors include his extensive industry knowledge and leadership experience dr boger brings an indepth knowledge of issues facing our company and our industry as a result of his experience founding and leading vertex and his distinguished career as a scientist source vertex pharmaceuticals incorporated on    sign up for equilar atlas and view joshua s boger phds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like joshua s boger phd more specifically youll be able to identify corporate executives in joshua s boger phds network and community follow changes in joshua s boger phds employment and moneyinmotion connect with joshua s boger phd through your network of conections view full profile   search for over  executive profiles bio example joshua s boger phd joshua s boger phds connections  sign up now to view joshua s boger phds  connections » n anthony coles board member mckesson corporation kenneth l horton former special counsel vertex pharmaceuticals incorporated ian f smith executive vice president chief operating officer and chief financial officer vertex pharmaceuticals incorporated jeffrey m leiden chairman of the board president and chief executive officer vertex pharmaceuticals incorporated richard h aldrich board member ovascience inc peter mueller former employee vertex pharmaceuticals incorporated adelene q perkins president chief executive officer and chairman of the board infinity pharmaceuticals inc freda c lewishall executive vice president and chief medical officer pfizer inc pfizer inc stuart a arbuckle executive vice president and chief commercial officer vertex pharmaceuticals incorporated darryl b hazel former board member alliant energy popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla daniel a dematteo executive chairman gamestop corp david j oconnor president and ceo the madison square garden company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   joshua s boger phd  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in joshua s boger phd board member at vertex pharmaceuticals incorporated view full profile are you joshua s boger phd claim your profile   sign up for equilar atlas and view joshua s boger phds full profile with equilar atlas you can identify corporate executives in joshua s boger phds network and community follow changes in joshua s boger phds employment and moneyinmotion connect with joshua s boger phd through your network of contacts joshua s boger phds executive work history current board member vertex pharmaceuticals incorporated past to view joshua s boger phds complete executive work history sign up now education ba wesleyan university ms harvard university age      joshua s boger phds biography dr boger is the founder of vertex and has been a director since our inception in  he was our chief executive officer from  through may  he was our chairman of our board of directors from  until may  and our president from our inception until december  and from  through february  he was our chief scientific officer from  until may  prior to founding vertex in  dr boger held the position of senior director of basic chemistry at merck sharp  dohme research laboratories in rahway new jersey where he headed both the department of medicinal chemistry of immunology  inflammation and the departm  read more dr boger is the founder of vertex and has been a director since our inception in  he was our chief executive officer from  through may  he was our chairman of our board of directors from  until may  and our president from our inception until december  and from  through february  he was our chief scientific officer from  until may  prior to founding vertex in  dr boger held the position of senior director of basic chemistry at merck sharp  dohme research laboratories in rahway new jersey where he headed both the department of medicinal chemistry of immunology  inflammation and the department of biophysical chemistry dr boger holds a ba in chemistry and philosophy from wesleyan university and ms and phd degrees in chemistry from harvard university skills and qualifications dr bogers qualifications for our board of directors include his extensive industry knowledge and leadership experience dr boger brings an indepth knowledge of issues facing our company and our industry as a result of his experience founding and leading vertex and his distinguished career as a scientist source vertex pharmaceuticals incorporated on    sign up for equilar atlas and view joshua s boger phds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like joshua s boger phd more specifically youll be able to identify corporate executives in joshua s boger phds network and community follow changes in joshua s boger phds employment and moneyinmotion connect with joshua s boger phd through your network of conections view full profile   search for over  executive profiles bio example joshua s boger phd joshua s boger phds connections  sign up now to view joshua s boger phds  connections » n anthony coles board member mckesson corporation kenneth l horton former special counsel vertex pharmaceuticals incorporated ian f smith executive vice president chief operating officer and chief financial officer vertex pharmaceuticals incorporated jeffrey m leiden chairman of the board president and chief executive officer vertex pharmaceuticals incorporated richard h aldrich board member ovascience inc peter mueller former employee vertex pharmaceuticals incorporated adelene q perkins president chief executive officer and chairman of the board infinity pharmaceuticals inc freda c lewishall executive vice president and chief medical officer pfizer inc pfizer inc stuart a arbuckle executive vice president and chief commercial officer vertex pharmaceuticals incorporated darryl b hazel former board member alliant energy popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla daniel a dematteo executive chairman gamestop corp david j oconnor president and ceo the madison square garden company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   joshua boger joins alkeus pharmaceuticals about us corporate profile management contact us medical conditions dryamd stargardt disease lebers optic neuropathy research visual cycle preclinical results clinical clinical trials stargardts registry expanded access news press releases alkeus pharma in the news publications careers current openings a a news press releases alkeus pharma in the news publications press release joshua boger joins alkeus pharmaceuticals joshua boger founder and retired ceo of vertex pharmaceuticals to serve as executive chairman boston massachusetts may   � alkeus pharmaceuticals inc alkeus pharma announced today that joshua boger phd has been appointed executive chairman of the company�s board of directors bringing over  years of experience in drug discovery development and commercialization dr boger joins for the first time another pharmaceutical company since he started vertex pharmaceuticals inc vertex in  and retired in may  as ceo of vertex he led the company�s efforts to develop sciencebased transformative medicines which have since turned the company into a successful global business alkeus pharma lead compound alk is an oral drug investigated as a treatment for stargardt disease the leading cause of juvenile macular degeneration alk has received clearance from the united states food and drug administration fda to initiate human clinical trials and the company is preparing a multicenter study to test whether alk could offer a clinical benefit to children and adults affected by stargardt disease interested individuals are welcome to register their names on alkeus pharma� pharma website wwwalkeuspharmacom stargardt disease is an untreatable and progressive genetic condition that leads to blindness in almost all of those who have it many patients experience first visual symptoms before the age of twenty the condition originates from a genetic mutation that causes malfunction of a protein used in the recycling of the vitamin a contained in the eye poor processing of vitamin a results in the formation of excessive toxic deposits in the eye followed by vision loss dysfunction of this protein has also been linked to agerelated macular degeneration amd the number one cause of blindness in the western world dr boger commented i have been impressed by alkeus pharma� leadership the progress achieved to date and the ambitious program i am eager to actively participate in the development of a treatment for a major cause of childhood blindness alk�s underlying science is one of the most elegant i have seen and the animal data corroborate its promise to treat stargardt disease we will work hard in collaboration with retinal experts to bring this drug through clinical trials joshua joins at a very exciting time his leadership experience and track record in the field of drug development including medicines for rare genetic diseases will be critical to our company�s future� added leonide saad phd president and ceo of alkeus pharma �joshua�s lifelong commitment to good science and to having an impact on patients� lives is admirable it is our greatest honor to welcome him aboard as we work relentlessly to develop treatments for blindness besides leading the way in the use of structurebased rational drug design as the basis for drug discovery dr joshua boger pioneered alliances between pharma companies and diseasefocused foundations by partnering with the cystic fibrosis foundation to discover and develop new cystic fibrosis cf medicines this resulted early  in the marketing approval of vertex first cf medicine one of the first oral drugs to address the root cause of a genetic condition beyond his role as executive chairman of alkeus pharma dr boger continues to serve on the board of vertex he is also the chair of the board of fellows of the harvard medical school chair of the board of trustees at wesleyan university chair of nehi the network for healthcare innovation cambridge board member of the biotechnology industry organization bio the whitehead institute for biomedical research the hastings center and the massachusetts life sciences center he is also the chair of the board of the celebrity series vicechair of the alliance for business leadership vicechair of the museum of science boston and serves on additional boards such as the harvard board of overseers the american civil liberties union of massachusetts foundation the science advisory council of wgbh the massachusetts workforce investment board and masschallenge prior to founding vertex dr boger worked for over a decade at merck dr boger holds a bachelor of arts in chemistry and philosophy from wesleyan university and a masters and doctorate degrees in chemistry from harvard university about alkeus pharmaceuticals inc alkeus pharmaceuticals is a clinical stage drug discovery and development company focused on firstinclass compounds to treat serious diseases of the eye its lead compound alk specifically targets the formation of toxic deposits found in the eyes of patients with stargardt disease    media contact infoalkeuspharmacom download this press release by clicking here about alkeus pharma corporate profile management contact us medical conditions dryamd stargardt disease lebers optic neuropathy research visual cycle preclinical results clinical clinical trials stargardts registry expanded access news press releases alkeus pharma in the news publications careers current openings    alkeus pharmaceuticals inc form  vertex pharmaceuticals for jun  filed by boger joshua s research stocks news story skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  news  events  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print format change text size default text sizea larger text sizea largest text sizea form  vertex pharmaceuticals for jun  filed by boger joshua s by k wizard—  pm et  httparchivefastedgarcomadzsegcwvzlzijzzuozrz filed on june   more vrtx news vertex to present at the goldman sachs healthcare conference on june  business wire   am et  vertex announces nine presentations of data on orkambi® lumacaftorivacaftor and kalydeco® ivacaftor at the european cystic fibrosis society ecfs conference business wire   am et  vertex names dr alan garber provost of harvard university to its board of directors business wire   pm et  copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top bofi log in for events hafc an earn epam sn log in for events chkp lho fit gts find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  am et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  vrtx stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsvrtx vertex pharmaceuticals inc    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all us stockswall st at new highs as tech breaches dotcom era record reuters –  pm et   sp  tech sector breaks record held since march   morgan stanley ms rises as profit beats expectations  csx forecast miss drags rail stocks lower  dow up  pct sp  up  pct nasdaq up  pct by rodrigo campos and kimberly chin global marketsworld stocks tally th day of gains as earnings pick up reuters –  pm et   us dollar edges off month low central banks eyed  nasdaq sp  hit records as european indexes gain  us yields little changed ahead of ecb meeting  oil prices jump on surprisingly big us inventory draws by lewis krauskopf us stockssp nasdaq at records as vertex rallies ibm slips reuters –  pm et   morgan stanley ms rises as profit beats expectations  csx forecast miss drags rail stocks lower  vertex at record high on cystic fibrosis treatment data  dow up  pct sp  up  pct nasdaq up  pct by rodrigo campos and kimberly chin global marketsworld stocks climb for th day as earnings kick in reuters –  pm et   us dollar edges off month low  nasdaq sp  hit records as european indexes gain  us yields little changed ahead of ecb meeting  oil rises on surprisingly big us inventory draws by lewis krauskopf us stockstech lifts nasdaq sp to record ibm weighs on dow reuters –  pm et   morgan stanley ms rises as profit beats expectations  csx forecast miss weighs on union pacific unp kansas city southern ksu  vertex at record high on positive cystic fibrosis treatment data  indexes up dow  pct sp  pct nasdaq  pct by tanya agrawal global marketsworld stocks run win streak to  days as earnings heat up reuters –  am et   us dollar edges off month low  wall street european stock indexes post gains  us yields little changed ahead of ecb meeting  oil jumps as big us inventory draws surprise by lewis krauskopf us stockstech lifts nasdaq sp to new highs ibm weighs on dow reuters –  am et   morgan stanley ms rises as quarterly profit beats expectations  ibm ibm falls as revenue misses estimates drags on dow  csx falls after forecast misses estimates  indexes up dow  pct sp  pct nasdaq  pct by tanya agrawal vertex stock rockets to record boosting market cap by  billion marketwatch –  am et  shares run up  as cystic fibrosis drug shows promise vertex pharmaceuticals inc vrtx shares soared wednesday adding over  billion to the companys market value as the biotech drug maker announced positive results from clinical studies of its cystic fibrosis treatments and boosted the companys probability of becoming a buyout target according to one analyst shares of bostonbased vertex rocketed  in morning trade hitting an alltime intraday high of  in the us stocksnasdaq sp hit record highs as tech health stocks rise reuters –  am et   morgan stanley ms rises as quarterly profit beats expectations  ibm ibm falls as revenue misses estimates weighs on dow  tmobile qualcomm qcom amex to report after the closing bell  indexes up dow  pct sp  pct nasdaq  pct by tanya agrawal vertex pharmaceuticals upgraded to outperform from market perform at raymond james marketwatch –  am et  us stockstech stocks lift nasdaq futures dow sp flat reuters –  am et   futures dow down  pts sp up  pts nasdaq up  pts a rise in technology stocks helped the nasdaq futures grind higher on wednesday while the sp and the dow futures were little changed with investors staying focused on earnings  the techheavy nasdaq closed at a record high on tuesday with the index posting its longest streak of gains since february  vertex pharmaceuticals stock fair value estimate set at  at janney marketwatch –  am et  vertex pharmaceuticals upgraded to buy from neutral at janney marketwatch –  am et  vertex soars  premarket after positive results from cysticfibrosis studies marketwatch –  am et  vertex pharma shares rally on cystic fibrosis drug study results marketwatch –  pm et  vertex pharmaceuticals inc vrtx shares surged in the extended session tuesday after the biotech drug maker announced positive results from clinical trials of its cystic fibrosis treatments vertex shares rallied  to  after hours the company said data from clinical studies of its treatment candidates vx and vx showed an up to  average improvement in lung function in cystic fibrosis patients given the drugs vertex skyrockets  after positive study on cystic fibrosis drug marketwatch –  pm et  briefvertex issues positive results from three different triple drug combination cystic fibrosis trials reuters –  pm et  vertex pharmaceuticals inc vrtx  vertex pharmaceuticals inc vrtx issues positive results from three different triple drug combination cystic fibrosis trials  vertex says all three triple combinations led to statistically significant improvement in lung function in studies  vertex says each combination included kalydeco and tezacaftor and a third experimental drug vertex reports positive results for cystic fibrosis triple combos reuters –  pm et  vertex pharmaceuticals inc vrtx on tuesday said three different triple combinations of cystic fibrosis treatments significantly improved patient lung function in clinical trials bolstering its goal of a therapy that could help up to  percent of patients with the lifeshortening lung disease vertex announces positive phase   phase  data from three different triple combination regimens in people with cystic fibrosis who have one fdel mutation and one minimal function mutation fdelmin business wire –  pm et  phase  data showed mean absolute improvements in ppfev of  and  percentage points for vx and vx respectively in triple combination with tezacaftor and ivacaftor in fdelmin patients initial data from phase  study showed mean absolute improvement in ppfev of  percentage points with vx triple combination in fdelmin patients first data to demonstrate the pote vertex awards two firstgeneration college students full scholarships to the university of massachusetts business wire –  am et  boston public high school students hannah mei and sayed shah receive vertex science leaders scholarship to pursue stem degrees at umass vertex boston public schools and the university of massachusetts today announced the recipients of the annual vertex science leaders scholarship a fouryear fullride scholarship to pursue an education in science technology engineering or math at any unive page page   next  todays and upcoming events jul  vrtx to announce q earnings after market confirmed jul  vrtx earnings conference call at  pm listen past events last  days jun  shareholders meeting data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe ﻿ joshua boger sold  worth of vertex pharmaceuticals incorporated nasdaqvrtx stock – octafinance monday  july  menu featured news  years ago  alphabet inc nasdaqgoogl tests its ad technology on billboards to cushion itself against ad blocks  years ago  china margin debt hits week high japan pumps’n’dumps as kyle bass fears looming em banking crisis  years ago  marc faber shares his insight in one hour exclusive interview he covers all from commodities and china to inflation the euro and gold  years ago  carl icahn criticizes the fed feels bad for investors buying junk bonds  years ago  john burbank european qe can’t save the markets same as the us quantitative easing everything will be liquidated joshua boger sold  worth of vertex pharmaceuticals incorporated nasdaqvrtx stock  by octastaff in blue chips insider news insider sells m share with your friendsyour nameyour emailrecipient emailenter a messagei read this article and found it very interesting thought it might be interesting for you the article is called joshua boger sold  worth of vertex pharmaceuticals incorporated nasdaqvrtx stock and is was published by octafinancecom at httpwwwoctafinancecomjoshuabogersoldworthofvertexpharmaceuticalsincorporatednasdaqvrtxstockcaptchasubmit joshua boger insider sell transaction vertex pharmaceuticals incorporated nasdaqvrtx    director and an insider joshua boger recently sold  company shares with a grand total value of  at the avg market share price which was  in the last  days he also unloaded  shares worth total  usd joshua boger now indirectly has rights to  shares he also directly has rights to  shares in total he holds a stake of  this insider transaction was made on  it’s available for a free review at the sec’s website and can be found at this page vertex pharmaceuticals inc ma stock rating sentiment and fundamentals it is difficult to make conclusions about vertex pharmaceuticals inc ma’s future just from joshua boger’s sale because in this filing the insider also revealed option transactions in the form it was reported that joshua exercised options for  shares with average price  worth  according to twenty five expert analysts that are covering the listed vertex pharmaceuticals inc ma’s future there is an expectation of per share earnings of  for the  year which gives vertex pharmaceuticals inc ma a price to earnings ratio of nan rating  sentimentpsychsignal socialsellanalysts ratingbuyhedge funds sentimentbuy stock fundamentalsearnings  fcf trendsellsectorindustry macrobullishvaluation models technical analysisst trenddownmt trenddownlt trenddown octafinance ratingsell  read how our stock ratings system works within the last  days the stock price of vertex pharmaceuticals inc ma has went down  and it is in a smooth bearish downtrend according to octafinance’s wellknow equities momentum system we can undisputedly rate it a “sell” alike joshua’s uptodate knowledge price chart of vertex pharmaceuticals incorporated nasdaqvrtx stock source rightedgesystems yahoo split  dividend adjusted data and octafinance interpretations popular stock traders who also include george soros once shared that the highest riskadjusted returns are made when both fundamental as well as technical analysis are combined hedge funds ownership information from q  sec filings disclose  institutional investors and hedge funds own vertex pharmaceuticals inc ma the institutional ownership of the company in q  is very high at  of the shares outstanding they decreased by  million the total shares they hold as of that quarter these stock owners owned  million shares there were  funds that created new positions and  funds that added to their positions a total of  funds closed their positions in vertex pharmaceuticals inc ma and  reduced their holdings according to sec’s f filings five institutional investors have the firm in their top  stock positions they are drw securities llc tekla capital management llc bb biotech ag arlington capital management inc ghost tree capital llc berkshire asset management llc pa had the greatest investment with ownership of  shares as of q  for  of the fund’s portfolio the stock is also  of the fund’s aum chilton capital management llc have  of their stock portfolio invested in the company for  shares in addition the massachusettsbased fund contravisory investment management inc revealed it had acquired a stake worth less than  of the fund’s stock portfolio in the company douglass winthrop advisors llc was also a big follower of the firm owning  shares vertex pharmaceuticals inc ma is  of the fund’s stock portfolio vertex pharmaceuticals incorporated nasdaqvrtx company profile vertex pharmaceuticals incorporated vertex is a global biotechnology company the company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs the company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis cf it is also engaged in other research and earlystage development programs including programs in the areas of oncology and neurology the company’s product candidates include kalydeco ivacaftor lumacaftor in combination with ivacaftor vx in combination with ivacaftor vx vx and vx the company’s product kalydeco is available in the market company website vertex pharmaceuticals incorporated vertex pharmaceuticals inc ma has  employees as of writing its market cap is  billion and it has  million outstanding shares currently it has  shareholders and the institutional ownership stands at  vertex pharmaceuticals inc ma was incorporated in massachusetts on  the stock closed at  yesterday and it had average  days volume of  shares it is down from the  days average shares volume of  vertex pharmaceuticals inc ma has a  weeks low of  and a one year high of  the stock price is below the  days sma vertex pharmaceuticals inc ma last issued its quarterly earnings stats on  the company reported  eps for the quarter missing the consensus estimate of  by  the company had a revenue of  million for  and  million for  therefore the revenue was  million up  transaction made pursuant to dr boger’s company approved trading plan under rule b  dr boger undertakes to provide upon request by the sec staff – the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price  fully vested vertex pharmaceuticals incorporated  receive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with marketbeatcoms free daily email newsletter tagged joshua bogervertex pharmaceuticals incorporated  nasdaqvrtx boulderado partners filing alex buffett rozek released oct  sec form analysts forecast higher teradyne inc ter eps vertex pharmaceuticals incorporated  get news  ratings daily enter your email address below to get the latest news and analysts ratings for vertex pharmaceuticals incorporated with our free daily email newsletter hedge fund newstop  citadel advisors f holdings in q df dent  co inc just released its q  stock positionsmaverick capital top  holdings in q analyzing ken griffins citadel advisors stock holdings in q lone pine capital top  f positions in q guru newsfelix zulauf sees a stock market correction coming this rally sp  indexspinx will be shortlivedmarc faber shares his insight in one hour exclusive interview he covers all from commodities and china to inflation the euro and goldjim grant the next thing might be helicopter money what to buy and where he sees investment opportunitieskyle bass bearish on emerging markets for at least  more years looking to short currenciesdavid tepper gets defensive is it time to get out of the stock market macro newschina margin debt hits week high japan pumps’n’dumps as kyle bass fears looming em banking crisisare us – russian relations a zerosum gameus and russia have launched direct talks on the conflict in syriayuan drops as pboc cuts reference rate by most since devaluationcould the market crash like —put volume spike argues low is nearctas newsred rock just published report about the trend following landscape  how ctas’ performance must be analyzedhow to implement dual momentum for nonus investorsdo commodity trading advisors ctas really provide crisis alpha equity hedge and are long volatility txt   hdrsgml    accession number  conformed submission type  public document count  conformed period of report  filed as of date  date as of change  issuer company data company conformed name vertex pharmaceuticals inc  ma central index key  standard industrial classification pharmaceutical preparations  irs number  state of incorporation ma fiscal year end  business address street   northern avenue city boston state ma zip  business phone  mail address street   northern avenue city boston state ma zip  reportingowner owner data company conformed name boger joshua s central index key  filing values form type  sec act  act sec file number  film number  mail address street   waverly street city cambridge state ma zip    docxml form  submission x     vertex pharmaceuticals inc  ma vrtx  boger joshua s co vertex pharmaceuticals incorporated  northern avenue boston ma      common stock   m    a  d common stock   s    d  d common stock   s    d  d common stock  i k common stock  i common stock held in trust stock option right to buy    m    d  common stock   d transaction made pursuant to dr bogers company approved trading plan under rule b dr boger undertakes to provide upon request by the sec staff the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price open market sales reported on this line occurred at a weighted average price of  range  to  open market sales reported on this line occurred at a weighted average price of  range  to  fully vested omar white attorneyinfact